Tags
recent advances
stemi
cabg
esc
pharmacotherapy
antiplatelet drugs
statins
2014
anticoagulants
antithrombotics
epilepsy
asthma
inflammatory bowel disease
ulcerative colitis
crohns disease
ibd
antocoagulants
statin adverse effects
cognitive dysfunction
cancer
metaanalysis
voyager
sudden cardiac death
scd
secondary prevention
risk management
risk stratification
acs
thrombolysis
reinfarction
pharmacoinvasive
migraine assessment
screening tools
assessment scales
migraine
microvascular cad
no reflow
patient education
corneal transplant
keratoplasty
hypertension
chf
heart failure
hocm
pci
hemodynamic support
aortic diseases
myocardial revascularization
dobutamine
2d echo
echocardiography
myocardial
myocardial viability
stress echo
dyslipidemia
diabetes
rima
bypass
lima
2015
guidelines
nstemi
See more
Presentations
(26)Likes
(2)VAP/HAP management guidelines by IDSA/ATS (2016) -: Dr.Tinku Joseph
Dr.Tinku Joseph
•
7 years ago
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
Dr Sandeep Kumar
•
7 years ago
Tags
recent advances
stemi
cabg
esc
pharmacotherapy
antiplatelet drugs
statins
2014
anticoagulants
antithrombotics
epilepsy
asthma
inflammatory bowel disease
ulcerative colitis
crohns disease
ibd
antocoagulants
statin adverse effects
cognitive dysfunction
cancer
metaanalysis
voyager
sudden cardiac death
scd
secondary prevention
risk management
risk stratification
acs
thrombolysis
reinfarction
pharmacoinvasive
migraine assessment
screening tools
assessment scales
migraine
microvascular cad
no reflow
patient education
corneal transplant
keratoplasty
hypertension
chf
heart failure
hocm
pci
hemodynamic support
aortic diseases
myocardial revascularization
dobutamine
2d echo
echocardiography
myocardial
myocardial viability
stress echo
dyslipidemia
diabetes
rima
bypass
lima
2015
guidelines
nstemi
See more